An observational study in Critical Illness and Brain Injuries, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Brain Injuries with a site in France — 18 open to participants now, 19 under way, none of them phase 3. Brain Injuries · France.
Among the 72 studies in Brain Injuries with a site in France, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2025, is one of 36 observational ones, reaches primary completion later than 5 of the 18 other live ones, and was the 63rd registered.
947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.
Browse Brain Injuries studies →18 of the 72 studies in Brain Injuries with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 17+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier St Anne · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 100 across 302 observational studies indexed under Brain Injuries.
Median enrollment 46 across the 36 interventional studies, 124 across the 36 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 72 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 1 study filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Brain Injuries with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07085403Hopitaux de Saint-MauriceLet's CO-OPerate! Together we Are Stronger | 2027-05-01 |
| NCT07127224Centre Hospitalier St AnneConsciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients) | 2027-05-05 |
| NCT07450404Central Hospital, Nancy, FrancePK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Brain Injuries with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Augmented Renal Clearance (ARC), defined as a supraphysiological increase in renal function, is frequently observed in critically ill patients, particularly those with acute brain injury. ARC complicates the management of renally eliminated drugs, specifically beta-lactam antibiotics, by enhancing drug clearance and thereby increasing the risk of underdosing and therapeutic failure. Although pharmacological therapeutic drug monitoring (TDM) is recommended to optimize dosing, it remains limited by issues of accessibility, highlighting the need for alternative approaches to identify at-risk patients and adjust dosing based on renal function.
Early identification of patients at risk for subtherapeutic beta-lactam plasma concentrations could enable timely dose adjustments. A combined assessment of renal function and beta-lactam TDM could enhance our understanding of the kinetics of both parameters. These data may support the development of predictive models capable of proposing individualized dosing regimens based on renal function.
Optimizing beta-lactam plasma concentrations in this patient population could improve infection management and potentially enhance clinical outcomes.
947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.
This study's planned enrollment of 140 is above the median of 100 across 302 observational studies indexed under Brain Injuries.
Browse Brain Injuries studies →Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Compared within Brain Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The population studied included patients admitted to the intensive care unit with acute brain injury (of traumatic, vascular, infectious or immunological origin), presenting a profile of HCR and receiving antibiotic treatment with betalactam
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (≥18 years) admitted to intensive care for acute brain injury, presenting with an infectious episode, documented augmented renal clearance (as assessed by urinary creatinine clearance), and receiving treatment with beta-lactam antibiotics.
Plasma betalactam underdosing
Development of a predictive model for plasma beta-lactam underdosing in critically ill patients with acute brain injury and renal hyperclearance, receiving beta-lactam therapy for an ongoing infectious episode. Plasma beta-lactam concentrations will be measured 24 hours after initiation of antibiotic therapy, and subsequently every 48 hours, or in cases of underdosing, overdosing, antibiotic switch, or significant changes in renal function.
Time frame: 24 hours after the start of antibiotic therapy, and repeated every 48 hours or in the event of underdosing, overdosing, change of molecule or significant variation in renal function, assessed until the antibiotic therapy is stopped, for up to 14 days
Evolution of Augmented Renal Clearance
Assessment of urinary creatinine clearance based on urine collection (8, 12, or 24-hour collection depending on center practices).
Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days
Evolution of plasma Beta-lactam Concentration
Monitoring of total plasma beta-lactam concentrations obtained through Therapeutic Drug Monitoring during the intensive care stay
Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days
Relationship Between Plasma Underdosing Intensity and Level of Augmented Renal Clearance (ARC)
Characterization of the intensity of plasma beta-lactam underdosing for each antibiotic molecule relative to the degree of ARC.
Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days
Beta-lactam Dosing According to Augmented Renal Clearance Level.
Development of a dosing nomogram for beta-lactam antibiotics tailored to the degree of ARC.
Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days
Clinical outcome
Assessment of clinical outcomes based on rates of clinical success and failure. * Clinical success is defined as the resolution of infectious symptoms present at the initiation of antibiotic therapy, allowing discontinuation of antibiotics at the end of the planned treatment duration. * Clinical failure is defined as the persistence or worsening of initial symptoms, the occurrence of superinfection (infection with newly identified pathogens), or recurrence (a new infectious episode with the same pathogen).
Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Nov 2025, 6 months after the start.
Of 144 non-industry observational studies under Brain Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 73. This study's planned 6 months is below that.
Counting every sponsor, half of 149 studies reached it within 31 months; a quarter within 16 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →